Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including lenacapavir—HIV’s ability to evolve resistance to the breakthrough antiviral.

Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...

During viral reproduction, the influenza polymerase (top left, in blue) scans along the ribonucleoprotein helix to produce messenger RNA. Credit: Science Like a camera-shy teenager, influenza’s ...

The technology, called the Viral-Engineered RNA-based Activation System (VERAS), hijacks the virus's own replication ...

Researchers at The Wistar Institute have identified a previously unknown mechanism by which viruses can reprogram mitochondrial structure to silence immune responses and ensure successful viral ...

Single-cell analysis helps uncover how the BK virus replicates, opening the door to new drug targets. BK polyomavirus (BKPyV) is a major cause of kidney transplant failure. Without a complete ...

Researchers have revealed the regulatory mechanism of a specific protein that plays a key role in balancing the immune response triggered by viral infections in mammal cells. These findings could help ...